Background And Objective: We evaluated the effects of dexmedetomidine pretreatment on bupivacaine cardiotoxicity in anesthetized rats.
Methods: Sixteen Wistar-Albino male rats (300-400 g) were anesthetized with ketamine. Electrocardiographic and invasive blood pressure monitoring were performed, and the results were continuously recorded. The rats were randomized into 2 groups. In group D, rats were pretreated with intravenous dexmedetomidine at a dose of 10 Kg/kg (n = 8), whereas in group S, rats were pretreated with intravenous saline (n = 8). Fifteen minutes later, bupivacaine was infused at a rate of 3 mg/kg per minute until cardiac asystole occurred. The timing of specific cardiotoxic events (a 25%, 50%, and 75% reductions of mean arterial pressure and heart rate as well as occurrence of the first arrhythmia and asystole) was recorded.
Results: Dexmedetomidine pretreatment reduced the heart rates and mean arterial pressures of the rats who received it (P G 0.05). Dexmedetomidine pretreatment before bupivacaine administration also significantly increased the time to the 25%, 50%, and 75% reductions in mean arterial pressure and the time to the 25% and 50% reductions in heart rate (P G 0.05). In addition, dexmedetomidine significantly increased the time to first arrhythmia and time to asystole (P G 0.05) in the rats who received it before receiving bupivacaine.
Conclusions: Dexmedetomidine pretreatment delays the effects of bupivacaine cardiotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/aap.0b013e3181bfbe35 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dexmedetomidine regulates the anti-oxidation and autophagy of adipose-derived stromal cells under HO-induced oxidative stress through Nrf2/p62 pathway and improves the retention rate of autologous fat transplantation.
Front Pharmacol
November 2024
Department of Plastic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
To investigate the protective mechanism of dexmedetomidine (DEX) on adipose-derived stromal cells (ADSCs) under oxidative stress model and its promotion effect on the retention rate of adipose granule transplantation by and experiments. The experiment was divided into control group, model group (ADSCs + HO+normal serum), DEX group (ADSCs + H0+DEX drug-containing serum), autophagy agonist group (ADSCs + HO+rapamycin (RAP)+normal serum), RAP + DEX group (ADSCs + HO+normal serum), RAP + DEX drug-containing serum), autophagy inhibitor group (ADSCs + HO+chloroquine (CQ)+normal serum), CQ + DEX group (ADSCs + HO+CQ + DEX drug-containing serum). HO-1, GSH-PX, SOD and CAT in ADSCs under oxidative stress model were measured.
View Article and Find Full Text PDFEffects and mechanisms of dexmedetomidine preconditioning on isoproterenol-induced ventricular arrhythmias.
Sci Rep
November 2024
Department of Anesthesiology, Ya 'an People's Hospital, Ya 'an, 625000, Sichuan, China.
Article Synopsis
- - Dexmedetomidine (DEX) is known for its sedative and anti-anxiety properties, and it shows promise in preventing and treating arrhythmias during surgery, although its exact mechanisms are still not fully understood.
- - In experiments with mice, DEX was found to reduce the occurrence of ventricular arrhythmias induced by a stressor (isoproterenol or ISO) by stabilizing key cardiac electrical properties like action potential duration and calcium transient duration.
- - DEX pretreatment improved cardiac conduction and decreased variability in calcium signaling, indicating that it helps maintain calcium homeostasis and could be beneficial in preventing stress-induced heart issues.
Objective: Insulin-like growth factor 1 (IGF-1) protects neuronal-cell damage by ischemia. Although neuronal cells have been reported to produce IGF-1, the molecular mechanisms remains obscure. Dexmedetomidine (DEX) protects neuronal cells from ischemic damage.
View Article and Find Full Text PDFDexmedetomidine preconditioning attenuates ferroptosis in myocardial ischemia-reperfusion injury via α2 adrenergic receptor activation.
Heliyon
November 2024
Department of Anesthesiology, Qingdao Women and Children's Hospital, School of Medicine, Shandong University, Jinan, China.
Objective: Dexmedetomidine (Dex) is a potent agonist of the α2 adrenergic receptor that has been shown to possess sedative and hypnotic properties. Dex can protect against myocardial ischemia-reperfusion injury (MIRI) by inhibiting ferroptosis. However, these studies were based on Dex post-conditioning, and the role of α2 adrenergic receptors in this process is unclear.
View Article and Find Full Text PDFDexmedetomidine Attenuates Neuroinflammation-Mediated Hippocampal Neurogenesis Impairment in Sepsis-Associated Encephalopathy Mice through Central α2A-Adrenoceptor.
ACS Chem Neurosci
November 2024
Department of Anesthesiology, Perioperative and Pain Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Article Synopsis
- * Dexmedetomidine has been shown to help mitigate the negative effects on neural stem cells (NSCs) caused by inflammatory factors from sepsis, improving NSC growth and survival in a dose-dependent manner, but its exact mechanism is still unclear.
- * In animal studies, dexmedetomidine countered the neuroinflammation and cognitive decline linked to SAE, with its protective effects potentially involving the inhibition of specific receptors related to astrocyte activity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!